Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04415151 · ClinicalTrials.gov registry record · Phase 2
Tofacitinib for Treatment of Moderate COVID-19
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04415151 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 24 participants.
The verdict
NCT04415151, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-99 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation.
Interventions
- DRUG Placebo
- DRUG Tofacitinib 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2021-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04415151
The ClinicalTrials.gov registry entry for NCT04415151 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04415151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04415151 about?
NCT04415151 is a clinical study titled "Tofacitinib for Treatment of Moderate COVID-19". The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-99 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mecha...
What is the current status of trial NCT04415151?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-10-14. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04415151?
The interventions under investigation include: Placebo (DRUG), Tofacitinib 10 mg (DRUG).
Who is sponsoring clinical trial NCT04415151?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.